Auriga Reiterates a 'Buy' on Jazz Pharmaceuticals (JAZZ) After Call With Patent Attorney
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $244.96 -0.36%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Auriga reiterates a 'Buy' on Jazz Pharmaceuticals (NASDAQ: JAZZ) price target of $57.00.
Analyst, Defei Yang, said, "For JAZZ to win the patent challenge case, it only needs one claim from one of the nine patents to be upheld. There are nine patents in litigation. Among them, three are formulation patents, one is method of use patent and five remaining patents are associated with distribution system. There are about thirty five claims spreading over nine patents. Patentability on REMS should have already been addressed. The U.S. Supreme Court, on June 28, 2010, decided the long-awaited Bilski case, affirming the Federal Circuit’s judgment. The Court ruled that a business process that if it is nothing more an abstract idea, it does not meet the patentability criteria. This decision has raised the bar on patent eligibility of business process. Our legal consultant thinks that distribution system patents are business process patents and thus Bilski case is a relevant reference point. Since three out of the five distribution patents (‘106, ‘107 and ‘171) are granted post the Bilski decision, it is highly likely that the three patents could sustain the challenge of the patentability test."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $44.27 yesterday.
Analyst, Defei Yang, said, "For JAZZ to win the patent challenge case, it only needs one claim from one of the nine patents to be upheld. There are nine patents in litigation. Among them, three are formulation patents, one is method of use patent and five remaining patents are associated with distribution system. There are about thirty five claims spreading over nine patents. Patentability on REMS should have already been addressed. The U.S. Supreme Court, on June 28, 2010, decided the long-awaited Bilski case, affirming the Federal Circuit’s judgment. The Court ruled that a business process that if it is nothing more an abstract idea, it does not meet the patentability criteria. This decision has raised the bar on patent eligibility of business process. Our legal consultant thinks that distribution system patents are business process patents and thus Bilski case is a relevant reference point. Since three out of the five distribution patents (‘106, ‘107 and ‘171) are granted post the Bilski decision, it is highly likely that the three patents could sustain the challenge of the patentability test."
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $44.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
